Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data

Journal of Epidemiology and Biostatistics

Volumn 6, Issue 3, 2001, Pages 243-265

  Bird, S M ^a   Goldberg, D J ^a   Hutchinson, S J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Combination therapy; HCV test uptake; Hepatitis C; HIV and overdose deaths; Incidence; Injection drug use; Late sequelae; Prevalence; Projections; Year of starting to inject

Indexed keywords

ALCOHOL; ALPHA INTERFERON; BENZODIAZEPINE DERIVATIVE; HEPATITIS C ANTIBODY; METHADONE; RIBAVIRIN;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; CANCER REGISTRY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG ABUSE; DRUG MISUSE; EPIDEMIC; FEMALE; HEALTH CARE PERSONNEL; HEALTH STATUS; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION RISK; INJECTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MEDICAL DOCUMENTATION; OUTCOMES RESEARCH; OUTPATIENT DEPARTMENT; PREGNANCY; PRISON; PRISONER; SALIVA ANALYSIS; UNITED KINGDOM; VIRUS CARRIER; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; GREAT BRITAIN; HEPATITIS C; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0035199835     PISSN: 13595229     EISSN: None     Source Type: Journal    
DOI: 10.1080/135952201317080661     Document Type: Article

References (110)

1. Transmission of hepatitis C: Rates, routes, and cofactors
2. Low risk of sexual transmission of hepatitis C virus
3. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin
4. Absence of hepatitis C transmission but frequent transmission of HIV-1 from sexual contacts of doubly infected individuals
5. Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study
6. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus
7. Epidemiology of hepatitis C virus infection among injecting drug users in Australia
8. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Virus Epidemic in Australia
9. Modelling the hepatitis C virus epidemic in Australia
10. Long-term outcome of hepatitis C infection after liver transplantation
11. Natural history of liver fibrosis progression in patients with chronic hepatitis C
12. Laboratory surveillance of hepatitis C virus infection in England and Wales: 1992 to 1996
13. A collaborative initiative between SCIEH and principal HCV testing laboratories through HEPC. Surveillance of known hepatitis C antibody positive cases in Scotland: Results to December 31, 1997
14. Use of monitored CD4 counts: Predictions of the AIDS epidemic in Scotland
15. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
16. Prevalence of hepatitis C carriage in Scottish prisons: Willing Anonymous Salivary Hepatitis C surveillance linked to self-reported risks
17. HIV, hepatitis and associated risk behaviour in the inmates of prisons in England and Wales; summary of results
18. HIV and AIDS Surveillance in Scotland. Review of the epidemic to December 1994
19. Unlinked Anonymous Surveys of hepatitis C
20. Hepatitis C antibody prevalence among injecting drug users in Glasgow has fallen but remains high
21. The incidence and prevalence of acquired immune deficiency syndrome and other severe HIV disease in England and Wales for 1992-97: Projections using data to end of June 1992
22. Anonymous HIV and risk-factor surveillance at Perth (for men) and Cornton Vale (for women) Prisons in Scotland
23. Harm reduction measures and injecting inside prison versus mandatory drugs tests: Results of a cross sectional anonymous questionnaire survey
24. Active paediatric surveillance of hepatitis C infection in the UK and Ireland
25. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: A national survey
26. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow, 1990-96: Is harm reduction working?
27. Prevalence of hepatitis C virus (HCV) among injection drug users in England and Wales: Is harm reduction working?
28. Detection of antibodies against hepatitis C virus in saliva: A marker of viral activity
29. Prevalence and epidemiological characteristics of hepatitis C in Scottish blood donors
30. Completed hepatitis C look back in Northern Ireland
31. Follow-up of blood donors positive for antibodies to hepatitis C virus
32. Asymptomatic infection with hepatitis C virus. Screening of blood donors is detecting people with unsuspected, but dangerous infection
33. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK)
34. Hepatitis C-related chronic liver disease among asymptomatic blood donors in the North West of England
35. Pilot study to estimate survivors to 1995 of 1983-84 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983-84
36. Prevalence of hepatitis C antibodies among healthcare workers in two teaching hospitals. Who is at risk?
37. Prevalence of hepatitis C antibodies in clinical health-care workers
38. National willing anonymous salivary HIV/Hepatitis B and C [WASH-BC] survey of prisoners in England and Wales
39. Low risk of sexual transmission of hepatitis C virus
40. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities
41. Hepatitis C and injecting drug use in prisons
42. Hepatitis C infection among injecting drug users attending the National Drug Treatment Centre
43. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users
44. Spread of blood-borne viruses among Australian prison entrants
45. Incidence of blood borne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995
46. Incidence and prevalence of clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus
47. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study
48. History of syringe sharing in prison and risk of Hepatitis B virus, hepatitis C virus, and Human Immunodeficiency Virus infection among injecting drug users in Berlin
49. HIV epidemiology in prisons: Anonymous voluntary HIV surveillance with risk factor elicitation
50. Study size and documentation to detect injection-related hepatitis C incidence in prison
51. Reduction in needle sharing among community wide samples of injecting drug users
52. Interventions with drug injectors in the UK: Trends in risk behaviour and HIV prevalence
53. Seroepidemiology of Hepatitis B virus in a population of injecting drug users
54. Rising incidence of hepatocellular carcinoma in the United States
55. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
56. EASL International Consensus Conference on hepatitis C. Consensus statement
57. Management of hepatitis C
58. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow-up
59. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
60. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
61. Marketing medicines through randomized controlled trials: The case of interferon
62. Risk factors and medical follow-up of drug users tested for hepatitis C-can the risk of transmission be reduced?
63. Medical practices regarding hepatitis C virus infection in Europe
64. The spectrum of hepatitis C antibody positive disease in a teaching hospital
65. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis
66. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients
67. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural net-work analysis of virus and clinical factors
68. Hepatitis C virus: Epidemiology and genotypes in the north-east of England
69. The association between hepatitis C virus genotype and human immunodeficiency virus progression in a cohort of hemophilic men
70. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus
71. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin
72. The prevalence of hepatitis B infection in adults in England and Wales
73. Acute hepatitis B infection in England and Wales: 1985-96
74. Hepatitis B vaccination: The cost effectiveness of alternative strategies in England and Wales
75. Hepatitis B vaccination policy in drug treatment services
76. The United Kingdom's hepatitis B immunisation strategy-where now?
77. More effective monitoring needed of young people's use of illegal drugs: Meta-analysis of UK trends
78. Sexual behaviour in Britain
79. Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland
80. An estimate of the prevalence of drug misuse in Liverpool and a spatial analysis of known addiction
81. Estimating the prevalence of drug misuse in Dundee, Scotland: An application of capture-recapture methods
82. Estimating the prevalence of opiate and benzodiazepine misuse in Grampian. A Report for Grampian Health Board
83. A sexual health ready reckoner. Summary indicators of sexual behaviour and HIV in London and South East England
84. Validation of a regional drug misuse database: Implications for future policy and surveillance of problem drug taking
85. Anonymous HIV surveillance in Saughton Prison
86. Study of infection with HIV and related risk factors in young offenders' institution
87. Drug misuse in Scotland: Findings from the 1993 and 1996 Scottish Crime Surveys
88. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-94
89. AIDS and Severe HIV-Related Disease in Scotland: Predictions to the end of 1999
90. The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: Projections using data to the end of 1994
91. Drug injection and HIV prevalence in inmates of Glenochil prison
92. HIV in Scotland to 31st December 1998
93. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis
94. Early mortality of undiagnosed but prevalent (in 1983-84) HIV infection in Lothian injectors who tested Hepatitis B surface antigen positive (group A) or negative but were high risk for blood-borne virus 1983-84
95. Pre-AIDS mortality in the Edinburgh City Hospital HIV Cohort
96. One year follow-up of opiate injectors treated with oral methadone in a GP-centred programme
97. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994
98. Mortality among injecting drug users: A critical reappraisal
99. NTORS at one year: Changes in substance abuse, health and criminal behaviour one year after intake
100. Death and survival in a cohort of heroin addicts from London clinics: A 22-year follow-up study
101. Identifying appropriate tasks for preregistration year: Modified Delphi technique
102. Extent and contributing factors of drug expenditure of injectors in Glasgow
103. Anonymous HIV surveillance with risk factor elicitation at Scotland's largest prison, Barlinnie
104. Bovine Creutzfeldt-Jakob disease? Failures of epidemiology must be remedied
105. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
106. Hepatitis C: Screening in pregnancy
107. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
108. Back-projection estimates of the number of dependent heroin users in Australia